Nutriband Inc. announced the exercise of 272,671 warrants at $6.43 each, raising approximately $1.75 million. The proceeds will support the clinical development and FDA submission of AVERSA Fentanyl, a potential first opioid patch with abuse-deterrent properties. This technology aims to prevent misuse and accidental exposure while maintaining patient access. Nutriband has no remaining tradeable warrants and is focused on advancing this innovative pharmaceutical product.
Nutriband Inc. announced the exercise of 272,671 warrants at $6.43 each, raising approximately $1.75 million. For readers following the Health sector, here is Pluang's market snapshot as of Oct 13, 2026 18:02 WIB: out of 128 priced US Health-sector stocks, 78 rose and 41 fell. Notable movers include NUWE at USD 0.66 with a 1-day change of -1.54%, DNA at USD 11.61 with a 1-day change of -1.53%, and SNN at USD 28.09 with a 1-day change of +1.52%.
Global Indemnity Group will postpone its third quarter 2026 earnings call originally scheduled for November 4 to January, when new CEO Jessica Buss will present her vision and priorities for the company. The company will still release its Q3 results ...
Lorraine Ben, former CEO of Lockheed Martin Canada, has joined Syntax Defence to provide expert counsel amid Canada's commitment to invest over half a trillion dollars in defence over the next decade. This includes $180 billion in procurement opportu...
Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...
Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
